# Teladoc Health, Inc.: overview

TDOC · NYSE · CIK 1477449 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tdoc.md) · [Financials](/companies/tdoc/financials.md) · [Filings](/companies/tdoc/filings.md) · [Insiders](/companies/tdoc/insiders.md)

Latest reported revenue: [$606.9m](/filings/0001477449-26-000038.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Jul 30, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001477449-26-000038).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [641](/filings/0001477449-25-000120.md) | [640 d](/filings/0001477449-26-000012.md) | [629](/filings/0001477449-26-000028.md) | [632](/filings/0001477449-26-000038.md) | [626](/filings/0001477449-25-000120.md) | [642 d](/filings/0001477449-26-000012.md) | [614](/filings/0001477449-26-000028.md) | [607](/filings/0001477449-26-000038.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(6.9%)](/filings/0001477449-25-000120.md) | [(7.5%) d](/filings/0001477449-26-000012.md) | [(19.2%)](/filings/0001477449-26-000028.md) | [(8.6%)](/filings/0001477449-26-000038.md) | [(8.3%)](/filings/0001477449-25-000120.md) | [(5.6%) d](/filings/0001477449-26-000012.md) | [(10.1%)](/filings/0001477449-26-000028.md) | [(6.1%)](/filings/0001477449-26-000038.md) |
| Net margin | % | [(5.2%)](/filings/0001477449-25-000120.md) | [(7.6%) d](/filings/0001477449-26-000012.md) | [(14.8%)](/filings/0001477449-26-000028.md) | [(5.2%)](/filings/0001477449-26-000038.md) | [(7.9%)](/filings/0001477449-25-000120.md) | [(3.9%) d](/filings/0001477449-26-000012.md) | [(10.4%)](/filings/0001477449-26-000028.md) | [(6.4%)](/filings/0001477449-26-000038.md) |
| Diluted EPS | $ per share | [(0.19)](/filings/0001477449-25-000120.md) | not reported | [(0.53)](/filings/0001477449-26-000028.md) | [(0.19)](/filings/0001477449-26-000038.md) | [(0.28)](/filings/0001477449-25-000120.md) | not reported | [(0.36)](/filings/0001477449-26-000028.md) | [(0.21)](/filings/0001477449-26-000038.md) |
| Free cash flow | $m | [109 d](/filings/0001477449-25-000120.md) | [79.8 d](/filings/0001477449-26-000012.md) | [13.2](/filings/0001477449-26-000028.md) | [90.2 d](/filings/0001477449-26-000038.md) | [97.0 d](/filings/0001477449-25-000120.md) | [85.1 d](/filings/0001477449-26-000012.md) | [7.9](/filings/0001477449-26-000028.md) | [63.7 d](/filings/0001477449-26-000038.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,033](/filings/0001477449-24-000023.md) | [2,407](/filings/0001477449-25-000005.md) | [2,602](/filings/0001477449-26-000012.md) | [2,570](/filings/0001477449-26-000012.md) | [2,530](/filings/0001477449-26-000012.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(13.1%)](/filings/0001477449-24-000023.md) | [(567.3%)](/filings/0001477449-25-000005.md) | [(9.6%)](/filings/0001477449-26-000012.md) | [(39.7%)](/filings/0001477449-26-000012.md) | [(10.4%)](/filings/0001477449-26-000012.md) |
| Net margin | % | [(21.1%)](/filings/0001477449-24-000023.md) | [(567.5%)](/filings/0001477449-25-000005.md) | [(8.5%)](/filings/0001477449-26-000012.md) | [(39.0%)](/filings/0001477449-26-000012.md) | [(7.9%)](/filings/0001477449-26-000012.md) |
| Diluted EPS | $ per share | [(2.73)](/filings/0001477449-24-000023.md) | [(84.60)](/filings/0001477449-25-000005.md) | [(1.34)](/filings/0001477449-26-000012.md) | [(5.87)](/filings/0001477449-26-000012.md) | [(1.14)](/filings/0001477449-26-000012.md) |
| Free cash flow | $m | [185](/filings/0001477449-24-000023.md) | [173](/filings/0001477449-25-000005.md) | [339](/filings/0001477449-26-000012.md) | [283](/filings/0001477449-26-000012.md) | [285](/filings/0001477449-26-000012.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/tdoc/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $137.6m | 16,223,134 |  | Added +1,609,578 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $107.6m | 12,685,592 |  | Added +390,498 |
| [Point72 Asset Management, L.P.](/funds/1603466.md) | 2026-06-30 | $69.9m | 8,239,927 |  | Added +518,432 |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $68.5m | 8,072,842 |  | Reduced −12,700 |
| [Voss Capital, LP](/funds/1730145.md) | 2026-06-30 | $68.2m | 8,046,679 |  | Added +3,846,679 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $67.5m | 7,955,032 |  | Added +97,863 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $62.5m | 7,371,699 |  | Added +1,073,294 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $42.1m | 4,962,382 |  | Added +602,631 |
| [AMERICAN CENTURY COMPANIES INC](/funds/748054.md) | 2026-06-30 | $41.5m | 4,894,504 |  | Added +1,438,120 |
| [Allianz Asset Management GmbH](/funds/1535323.md) | 2026-06-30 | $39.6m | 4,666,596 |  | Reduced −124,767 |

## Recent filings

[All 1,579 filings](/companies/tdoc/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-28 | 16:04 ET | [8-K](/filings/0001477449-26-000050.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001477449-26-000050 |
| 2026-09-25 | 08:30 ET | [8-K](/filings/0001477449-26-000046.md) | 5.02 Departure or appointment of officers or directors | 0001477449-26-000046 |
| 2026-08-31 | 16:35 ET | [8-K](/filings/0001477449-26-000044.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001477449-26-000044 |
| 2026-08-13 | 16:05 ET | [8-K](/filings/0001477449-26-000042.md) | 5.02 Departure or appointment of officers or directors | 0001477449-26-000042 |
| 2026-08-03 | 16:31 ET | [8-K](/filings/0001477449-26-000040.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001477449-26-000040 |
| 2026-07-30 | 09:54 ET | [10-Q](/filings/0001477449-26-000038.md) | Quarterly report, period 2026-06-30 | 0001477449-26-000038 |
| 2026-07-29 | 16:05 ET | [8-K](/filings/0001477449-26-000036.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001477449-26-000036 |
| 2026-05-21 | 16:04 ET | [8-K](/filings/0001477449-26-000030.md) | 5.07 Shareholder vote results | 0001477449-26-000030 |
| 2026-04-30 | 09:49 ET | [10-Q](/filings/0001477449-26-000028.md) | Quarterly report, period 2026-03-31 | 0001477449-26-000028 |
| 2026-04-29 | 16:05 ET | [8-K](/filings/0001477449-26-000026.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001477449-26-000026 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001477449-26-000012.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, locked when the 8-K was accepted. It is scored when the 10-Q or 10-K is ingested. [See the target](/leagues/2026q3/targets/47873c83-0b97-4e37-9a88-37fb63717e04)

## About the filer

- CIK: 1477449
- Tickers: TDOC
- Exchange: NYSE
- SIC code: 8011 Services-Offices & Clinics of  Doctors of  Medicine
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 10:31 ET. No prices; not investment advice.